These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 15371389)

  • 21. Health care expenditures associated with autism spectrum disorders.
    Leslie DL; Martin A
    Arch Pediatr Adolesc Med; 2007 Apr; 161(4):350-5. PubMed ID: 17404131
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Out-of-pocket health spending and the rural underinsured.
    Ziller EC; Coburn AF; Yousefian AE
    Health Aff (Millwood); 2006; 25(6):1688-99. PubMed ID: 17102195
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Health spending in OECD countries: obtaining value per dollar.
    Anderson GF; Frogner BK
    Health Aff (Millwood); 2008; 27(6):1718-27. PubMed ID: 18997231
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Health care cost growth among the privately insured.
    Bundorf MK; Royalty A; Baker LC
    Health Aff (Millwood); 2009; 28(5):1294-304. PubMed ID: 19738244
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Drug spending keeps rising, but rate of increase slowing.
    Capitation Rates Data; 2001 Aug; 6(8):85-9. PubMed ID: 11526857
    [No Abstract]   [Full Text] [Related]  

  • 26. Prescription drug spending trends in the United States: looking beyond the turning point.
    Aitken M; Berndt ER; Cutler DM
    Health Aff (Millwood); 2009; 28(1):w151-60. PubMed ID: 19088102
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prescription drug spending: contribution to health care spending and cost containment strategies.
    Rivers PA; Hall NG; Frimpong J
    J Health Care Finance; 2006; 32(3):8-19. PubMed ID: 18975728
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The impact of population ageing on future Danish drug expenditure.
    Kildemoes HW; Christiansen T; Gyrd-Hansen D; Kristiansen IS; Andersen M
    Health Policy; 2006 Feb; 75(3):298-311. PubMed ID: 16399170
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Infliximab drug and infusion costs among patients with Crohn's disease in a commercially-insured setting.
    Ollendorf DA; Lidsky L
    Am J Ther; 2006; 13(6):502-6. PubMed ID: 17122530
    [TBL] [Abstract][Full Text] [Related]  

  • 30. US spending on prescription drugs rose by 19% in 2000.
    Charatan F
    BMJ; 2001 May; 322(7296):1198. PubMed ID: 11358763
    [No Abstract]   [Full Text] [Related]  

  • 31. Estimates of the direct cost per case and overall burden of trichomoniasis for the employer-sponsored privately insured women population in the United States, 2001 to 2005.
    Owusu-Edusei K; Tejani MN; Gift TL; Kent CK; Tao G
    Sex Transm Dis; 2009 Jun; 36(6):395-9. PubMed ID: 19556934
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Healthcare utilization and costs of patients with rosacea in an insured population.
    Romanowicz M; Stephenson JJ; Del Rosso JQ; Lenhart G
    J Drugs Dermatol; 2008 Jan; 7(1):41-9. PubMed ID: 18246697
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Tracking health care costs: continued stability but at high rates in 2005.
    Ginsburg PB; Strunk BC; Banker MI; Cookson JP
    Health Aff (Millwood); 2006; 25(6):w486-95. PubMed ID: 17018565
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Spending on medicines in Israel in an international context.
    Sax P
    Isr Med Assoc J; 2005 May; 7(5):286-91. PubMed ID: 15909459
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Health care utilization and expenditures for privately and publicly insured children with sickle cell disease in the United States.
    Mvundura M; Amendah D; Kavanagh PL; Sprinz PG; Grosse SD
    Pediatr Blood Cancer; 2009 Oct; 53(4):642-6. PubMed ID: 19492318
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Treatment for substance use disorders in a privately insured population under managed care: costs and services use.
    Greenfield SF; Azzone V; Huskamp H; Cuffel B; Croghan T; Goldman W; Frank RG
    J Subst Abuse Treat; 2004 Dec; 27(4):265-75. PubMed ID: 15610828
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The economic burden of pervasive developmental disorders in a privately insured population.
    Flanders SC; Engelhart L; Whitworth J; Hussein MA; Vanderpoel DR; Sandman T
    Manag Care Interface; 2006 Aug; 19(8):39-45. PubMed ID: 16933527
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Health care expenditures of children and adults with spina bifida in a privately insured U.S. population.
    Ouyang L; Grosse SD; Armour BS; Waitzman NJ
    Birth Defects Res A Clin Mol Teratol; 2007 Jul; 79(7):552-8. PubMed ID: 17335056
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The impact of Medicare Part D on prescription drug use by the elderly.
    Lichtenberg FR; Sun SX
    Health Aff (Millwood); 2007; 26(6):1735-44. PubMed ID: 17978393
    [TBL] [Abstract][Full Text] [Related]  

  • 40. How much do we spend on prescription medicines? Out-of-pocket costs for patients in Australia and other OECD countries.
    Kemp A; Preen DB; Glover J; Semmens J; Roughead EE
    Aust Health Rev; 2011 Aug; 35(3):341-9. PubMed ID: 21871197
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.